Regeneron Reports Third Quarter 2020 Financial and Operating Results
The Pharma Data
NOVEMBER 5, 2020
Lastly, we are proud that our novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola, underscoring the potential of antibody therapies to address deadly infectious diseases.” REGN-COV2 , a dual antibody therapy to SARS-CoV-2 virus. Evinacumab , an antibody to ANGPTL3.
Let's personalize your content